New Triple-Threat therapy tested for tough head and neck cancers
NCT ID NCT05280457
Summary
This study is testing a three-part treatment for people with advanced head and neck cancer linked to HPV that has come back or spread. The treatment combines a DNA vaccine designed to target the virus, an immune-boosting drug (GX-I7), and an established immunotherapy (nivolumab). The main goal is to see if this combination can shrink tumors and control the cancer in patients whose disease progressed after standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.